- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S8976
| Related Targets | Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism |
|---|---|
| Other Serine/threonin kinase Products | WNK463 SRPIN340 Benzamidine HCl SPHINX31 GCN2iB WNK-IN-11 14-3-3 η Antibody [G4H24] MKI-1 STK16-IN-1 2OH-BNPP1 |
|
In vitro |
DMSO
: 95 mg/mL
(180.08 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 527.54 | Formula | C26H28F3N7O2 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 2222635-15-4 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | COC1=C(NC2=NC=C3N(CC(F)(F)F)C(=O)C4=CC=CC=C4N(C)C3=N2)C=CC(=C1)N5CCN(C)CC5 | ||
| Targets/IC50/Ki |
DCLK1
(Cell-free assay) 9.5 nM
DCLK2
(Cell-free assay) 31 nM
DCLK1
(kinase assay) 57.2 nM
DCLK2
(kinase assay) 103 nM
|
|---|---|
| In vitro |
DCLK1-IN-1 displays pronounced on-target DCLK1 activity in vitro. This compound potently binds DCLK1 in HCT116 cells (IC50 = 279 nM). It significantly inhibits DCLK1, and weakly inhibits ERK5, in PATU-8988T cell lysates and live cells. |
| In vivo |
DCLK1-IN-1 has a favorable pharmacokinetic profile in mice, with a half-life of 2.09 h, an area under the curve of 5,506 h ng−1 ml−1 and 81% oral bioavailability. This compound is well-tolerated at doses up to 100 mg kg−1 with no adverse effects and no loss of body weight observed in mice. It is a selective inhibitor of DCLK1, suitable for use as a chemical probe when used together with control compound DCLK1-NEG. |
References |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.